BY OUR PLATFORMS
BY THERAPEUTIC AREA
20 December 2022
These projects are intended to support industrial research projects carried out in cooperation between companies and R&D agents, both public and private, in order to respond to the challenges identified in the thematic priorities topics.
24 out of the 61 approved projects (36% of total) are classified as "biotech." ZeClinics is one of the 17 Asebio partners (including 9 companies and 7 entities) that have benefited from these public resources in the current call.
Biotech numbers in the 17 thematic priorities:
For the priority Development of new alternative methods to reduce animal experimentation, 10 projects have been awarded, representing 15% of the total. These projects have received a total of 4.3 million euros (12%) in the form of a grant and 1.4 million euros (10%) in the form of a loan.
For the priority New approaches to understand the mechanisms and establish new strategies for solid tumor cancer immunotherapy, 8 projects have been awarded, representing 12% of the total. These projects have received a total of 5.2 million euros (15%) in the form of a grant and 3.9 million euros (26%) in the form of a loan.
For the priority Safe physical methods for the diagnosis and treatment of diseases, a total of 7 projects have been awarded, representing 10%. These projects have received a total of 4.4 million euros (12.4%) in the form of a grant and 1.3 million euros (9.3%) in the form of a loan.